Clinical trial · no report yet · Phase 1/Phase 2
MyDRUG
Myeloma-Developing Regimens Using Genomics (MyDRUG)
- NCT03732703 ↗
- Completed
- Multiple Myeloma Research Consortium
- 14 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| X threads | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Relapsed Refractory Multiple Myeloma
- Interventions
- Abemaciclib, dexamethasone, ixazomib, pomalidomide; Enasidenib, dexamethasone, ixazomib, pomalidomide; Cobimetinib, dexamethasone, ixazomib, pomalidomide; Erdafitinib, dexamethasone, ixazomib, pomalidomide; Venetoclax, dexamethasone, ixazomib, pomalidomide; Daratumumab, dexamethasone, ixazomib, pomalidomide; Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide; Selinexor, dexamethasone, ixazomib, pomalidomide
- Arms
- Sub-Protocol A1 · Experimental
- Sub-Protocol B1 · Experimental
- Sub-Protocol C1 · Experimental
- Sub-Protocol D1 · Experimental
- Sub-Protocol E1 · Experimental
- Sub-Protocol Y1 · Experimental
- Sub-Protocol Y2 · Experimental
- Sub-Protocol Y3 · Experimental
- Enrollment
- 103
- Primary outcomes
- Overall Response Rate - Actionable Genetic Alteration
- Overall Response Rate - Non-Actionable Genetic Alteration
- Sponsor
- Multiple Myeloma Research Consortium with AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
- Start
- Apr 1, 2019
- Primary completion
- Dec 31, 2024
- Results posted
- No
- Registry record
- NCT03732703 · updated Feb 14, 2025
Publications
linked from the registry- Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. PubMed 27511158